1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shenzhen Lifotronic Technology Co., Ltd. Class A

Shenzhen Lifotronic Technology Co., Ltd. Class A

SSSE:688389
11.03
CNY
-0.01
(-0.09%)
0.39EPS
24.59P/E
4.19BMarket Cap
Oct 30Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.41
0.69
0.84
1.09
1.31
1.84
2.35
2.68
2.69
2.42
2.77
Basic EPS, GAAP
0.02
0.13
0.21
0.26
0.34
0.45
0.6
0.77
0.81
0.43
0.4
Free Cash Flow per Basic Share
-0.01
-0.23
0.02
0.06
0.19
0.14
0.21
0.6
0.55
0.46
- -
Dividend per Share
0.01
- -
- -
0.16
0.12
0.18
0.18
0.24
0.29
0.28
- -
Book Value per Share
0.98
1.55
1.76
2.49
2.71
2.97
3.41
4.2
4.79
4.94
4.85
Tangible Book Value per Share
0.94
1.51
1.53
2.27
2.45
2.62
3.02
3.86
4.47
4.65
4.57
Basic Weighted Avg Shares
422
366
386
387
423
423
419
427
426
428
423
Sales/Revenue/Turnover
175
251
323
423
554
778
983
1,146
1,148
1,038
1,171
Operating Margin (%)
-6.52
19.13
23.53
23.92
25.56
25.21
23.04
30.94
31.8
18.1
18.86
Depreciation Expense
4
6
7
9
12
21
27
28
36
39
- -
Net Income, GAAP
10
48
81
101
144
190
251
329
345
184
168
Effective Tax Rate (%)
15.37
12.62
9.51
10.99
7.84
6.27
2.08
4.94
9.61
0.84
1.4
Profit Margin (%)
5.66
18.97
25.09
23.79
25.99
24.46
25.58
28.68
30.09
17.75
14.38
Working Capital
375
473
475
790
824
806
826
1,131
1,341
1,261
1,151
LT Debt
- -
- -
- -
- -
1
1
- -
2
- -
1
2
Total Equity
371
587
668
1,050
1,144
1,258
1,443
1,798
2,049
2,109
2,068
Return on Invested Capital (%)
- -
9.82
12.74
11.62
13.06
15.63
17.47
17.89
14.46
6.91
6.51
Return on Capital (%)
- -
10.06
12.93
11.7
13.1
15.83
17.75
18.37
15.01
7.41
7.01
Return on Common Equity (%)
- -
9.93
12.92
11.71
13.13
15.87
18.66
20.3
17.95
8.84
8.05

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
397
149
260
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
428
428
428
Market Capitalization
5,562
5,228
4,195

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,957
1,645
1,698
Cash, Cash Equivalents & STI
1,574
1,265
1,310
Accounts Receivable, Net
174
171
175
Inventories
183
183
183
Total Current Liabilities
697
379
547
Payables & Accruals
- -
- -
- -
ST Debt
397
149
260
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.24%
2.9%
Free Cash Flow
- -
36.98%
-15.75%
Net Income, GAAP
- -
10.69%
-46.66%
Sales/Revenue/Turnover
- -
14.8%
-9.6%
Total Cash Common Dividend
- -
- -
-3.38%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
306
284
267
291
1,148
2025
215
292
- -
275
1,038
2026
260
344
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.25
0.15
0.2
0.21
0.81
2025
0.13
0.16
- -
0.05
0.43
2026
0.08
0.11
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.29
2025
- -
- -
- -
- -
0.28
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ming Long Hu
Full Time Employees
1,756
Sector
Health technology
Industry
Medical specialties
Address
Pumen Technology Headquarters Building, No. 8 Shenzhen GD China 518000
IPO Date
Nov 5, 2019
Website
lifotronic.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shenzhen Lifotronic Technology Co., Ltd. is a technology company specializing in the research, development, manufacturing, and sales of advanced medical and aesthetic devices. Its core product portfolio includes medical aesthetic instruments, physiotherapy and rehabilitation equipment, beauty care and skin treatment devices, and laser therapy machines. The company's offerings encompass a wide range of categories such as ultrasonic therapy devices, radiofrequency devices, IPL (Intense Pulsed Light) systems, cryolipolysis (fat-freezing) machines, and adipolysis equipment designed for non-invasive body slimming and skin rejuvenation. Lifotronic operates primarily in China but maintains a global presence by serving customers across Asia, Europe, and other international markets. Founded in 2003 and headquartered in Shenzhen, Guangdong Province, the company continues to expand its technological capabilities and market reach. In recent years, Shenzhen Lifotronic Technology has strategically enhanced its offerings through new product launches that incorporate cutting-edge technologies in non-invasive medical aesthetics. The company has also entered into key partnerships and strategic collaborations to augment its R&D capabilities and distribution channels, leveraging innovations in laser and energy-based devices to broaden its product lineup. Additionally, Lifotronic has increased its operational efficiency by optimizing manufacturing processes and expanding production capacity, aligning with its goal to solidify its competitive positioning in the global medical aesthetic and rehabilitation device markets. These developments reflect the company's commitment to technological innovation and market expansion since 2023.